I love this $20 Amazon ice roller for depuffing my face and tons of other benefits
More than just a beauty product, the Esarora ice roller offers an instant cool-down for your face and body. It depuffs, sculpts and tightens the skin for an easy anti-aging treatment, but it also helps with aches, pains and other discomfort from head to toe. Come summertime, the frozen tool is great for keeping cool and comfortable on hot days too.
After a year of using this Amazon gadget, I'm sharing why I consider it one of the best ice rollers out there.
Esarora Ice Roller
Keep this editor- and celebrity-loved ice roller in your freezer for an on-demand depuffing treatment. The chilled roller also helps with calming inflamed skin, easing aches and pains, combatting hot flashes and more. The Esarora ice roller has been on my radar for years. In the early 2020s, it seemed to be one of those inescapable Amazon hits that bloggers and celebrities swore by (see model and entrepreneur Karlie Kloss using it on Jimmy Fallon below). The skin care tool has also garnered attention on TikTok as at-home facial treatments, from chemical peels to dermarolling, have gained popularity, leaving users in need of a quick fix to soothe and calm skin.
A post shared by Jimmy Fallon (@jimmyfallon) Along with all this fanfare are the Amazon reviews — over 22,000 of them, amounting to an overall 4.6-star rating. I read through pages and pages of the glowing reviews, learning about all the ways people use the ice roller: for depuffing, inflamed skin, muscle soreness, hot flashes, migraines, hangovers, sinus pressure, joint pain, overheated/flushed faces, post-medical procedures and more. I didn't need any more convincing to order the Esarora ice roller last summer.
I've tested a number of cryotherapy tools and ice rollers over the years and the Esarora remains a favorite. At $20, it's one of the cheapest I've found, and I like it even better than some of the pricier alternatives.
The Esarora roller is a bit bigger than you'd expect for a facial massager, but that extra surface area is what makes it so versatile. It effortlessly glides across my face, never pulling or tugging at my skin, and leaves me looking more sculpted, awake and glowy. Essentially, the cooling treatment increases circulation and the massaging action helps promote lymphatic drainage. But its depuffing power is just the beginning of its benefits. It feels great on my shoulders and neck when I have tension, and I've also used it to calm down mosquito bites all over my body. My face tends to get hot and red when I work out, so I love pulling out the ice roller to cool down too.
The tool is truly effortless to use. As long as you keep it in the freezer, you'll have instant cryotherapy. The frozen gel part of the tool stays cold for over an hour, which really impressed me. I've tried stainless steel ice rollers that are incredibly cold (almost disagreeably so) that rise to room temp in half that time. If you want different cold intensity levels, the Esarora ice roller also comes in a set with both a gel head and a stainless steel head.
If I'm nitpicking, the only thing I don't love about the Esarora ice roller is its bulky handle. It's not the most ergonomically comfortable to hold, but that doesn't detract from how effective the tool is overall.
Over the past year, the Esarora ice roller has become a fixture of my freezer. One of my favorite ways to use it is to enhance my skin prep, especially in the summertime. Gliding the ice roller over a calming sheet mask never fails to revive my skin after I've gotten too much sun.
How do you use the Esarora ice roller?
How do you use the Esarora ice roller?
For the initial use, place the roller head in the freezer overnight or for at least an hour so it freezes. Once it's nice and cold, all you have to do is attach the head to the handle and glide it over any area you want to treat.
I keep my entire ice roller, handle and all, in the freezer so it's ready to go whenever I want to depuff and cool down.
How many times a week should you use an ice roller?
How many times a week should you use an ice roller?
You can use an ice roller as often as you wish. Reaching for it in the morning, when the face is typically the puffiest, will help get your circulation going and combat any swelling.
Do dermatologists recommend ice rollers?
Do dermatologists recommend ice rollers?
Yes — in fact, two dermatologists shared the many beauty benefits of using cryotherapy tools in our guide to the best ice rollers.
CNN Underscored has a team of skilled writers and editors who have many years of experience testing, researching and recommending products, and they ensure each article is carefully edited and products are properly vetted. We talk to top experts when applicable to make certain we are testing each product accurately, recommending only the best products and considering the pros and cons of each item. For this story, beauty and fashion editor Sophie Shaw tested the Esarora ice roller.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
27 minutes ago
- Associated Press
Kennedy names 8 vaccine committee replacements, including COVID shot critic
NEW YORK (AP) — U.S. Health Secretary Robert F. Kennedy Jr. on Wednesday named eight new vaccine policy advisers to replace the panel that he abruptly dismissed earlier this week. They include a scientist who researched mRNA vaccine technology and transformed into a conservative darling for his criticisms of COVID-19 vaccines, and a leading critic of pandemic-era lockdowns. Kennedy's decision to 'retire' the previous 17-member panel was widely decried by doctors' groups and public health organizations, who feared the advisers would be replaced by a group aligned with Kennedy's desire to reassess — and possibly end — longstanding vaccination recommendations. The new appointees to the Advisory Committee on Immunization Practices include Dr. Robert Malone, the former mRNA researcher who emerged as a close adviser to Kennedy during the measles outbreak. Malone, who runs a wellness institute and a popular blog, rose to popularity during the COVID-19 pandemic as he relayed conspiracy theories around the outbreak and the vaccines that followed. He has appeared on podcasts and other conservative news outlets where he's promoted unproven and alternative treatments for measles and COVID-19. He has claimed that millions of Americans were hypnotized into taking the COVID-19 shots. He's even suggested that those vaccines cause a form of AIDS. He's downplayed deaths related to one of the largest measles outbreaks in the U.S. in years. Other appointees include Dr. Martin Kulldorff, a biostatistician and epidemiologist who was a co-author of the Great Barrington Declaration, an October 2020 letter maintaining that pandemic shutdowns were causing irreparable harm. Dr. Cody Meissner, a former ACIP member, also was named. Kennedy made the announcement in a social media post on Wednesday. The committee, created in 1964, makes recommendations to the director of the Centers for Disease Control and Prevention. CDC directors almost always approve those recommendations on how Food and Drug Administration-cleared vaccines should be used. The CDC's final recommendations are widely heeded by doctors and determine the scope of vaccination programs. ___ Associated Press reporter Amanda Seitz contributed to this report. ___ The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute's Science and Educational Media Group and the Robert Wood Johnson Foundation. The AP is solely responsible for all content.
Medscape
an hour ago
- Medscape
Taletrectinib Approved for NSCLC
The FDA has approved taletrectinib (Ibtrozi, Nuvation Bio) for locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) in first- and later-line settings, regardless of prior ROS1 tyrosine kinase inhibitor (TKI) exposure. Taletrectinib is considered a next-generation ROS1 TKI to distinguish it from two first-generation products already on the US market: crizotinib and entrectinib. A third ROS1 TKI approved in 2023, repotrectinib, is also a next-generation medicine. Like repotrectinib, FDA granted taletrectinib a breakthrough therapy designation. Compared with crizotinib and entrectinib, Nuvation Bio data suggests taletrectinib has greater brain penetration, lower incidence of neurologic adverse events, less likelihood of resistance, and other benefits, plus a possible safety and efficacy edge over next-generation rival repotrectinib. 'Taletrectinib will likely become the preferred treatment option for advanced ROS1+ NSCLC,' commented Thomas E. Stinchcombe, MD, an associate editor at the Journal of Clinical Oncology , in the 'Context' section of his journal's publication of a pooled analysis of Nuvation Bio's two approval studies, TRUST-I and TRUST-II, in April. Taletrectinib was originally developed in China and was approved there in Jan 2025 for the same indication granted by FDA. The company plans a US launch in mid-2025, they stated in a press release. About 2% of NSCLC patients have ROS1-positive disease, and about a third of them present with brain metastases. ROS1-positive patients have an oncogenic rearrangement in the ROS1 gene, which leads to an abnormal ROS1 fusion protein that drives cancer growth. ROS1 TKIs block the protein's activity. The drug's approval was based on results of TRUST-I and TRUST-II, phase 2, single-arm, open label studies in ROS1-positive NSCLC patients treated with oral taletrectinib 600 mg once daily until progression, unacceptable toxicity, death, or consent withdrawal. Of the 273 subjects in the pooled analysis, 93.8% had stage IV disease, 33.7% had brain metastases, and 27.1% had received chemotherapy. TRUST-I included Chinese subjects who were either new to TKIs or who had received crizotinib. TRUST-II included patients from North America, Europe, and Asia who were TKI-naive or who had been treated with crizotinib or entrectinib. The efficacy population included 157 patients (103 in TRUST-I; 54 in TRUST-II) who were naive to treatment with a ROS1 TKI and 113 patients (66 in TRUST-I; 47 in TRUST-II) who had received one prior ROS1 TKI. Patients may have received prior chemotherapy for advanced disease. For treatment-naive patients, the overall response rate (ORR) was 90% in TRUST-I and 85% in TRUST-II, with 72% and 63% of responders having a duration of response (DOR) of at least a year, respectively. For TKI-pretreated patients, ORR was 52% in TRUST-I and 62% in TRUST-II, with 74% and 83% of responders having a DOR of at least 6 months, respectively. Among 13 patients with a G2032R mutation, which triggers resistance to first generation ROS1 TKIs, eight (61.5%) had a response to taletrectinib. In a safety analysis with 352 patients, the most frequent treatment-emergent adverse events with taletrectinib were gastrointestinal problems (88%) and elevated aspartate aminotransferase (72%) and alanine aminotransferase (68%). Neurologic adverse events included dizziness (21%) and dysgeusia (15%). Overall, 33% of patients had grade 3 or higher treatment-related adverse events. Treatment-emergent adverse events led to discontinuation in 7% of patients. There were three treatment-related deaths due to abnormal hepatic function, liver failure, and pneumonia. Prescribing information for taletrectinib includes warnings and precautions for hepatotoxicity, interstitial lung disease/pneumonitis, QTc interval prolongation, hyperuricemia, myalgia with creatine phosphokinase elevation, skeletal fractures, and embryo-fetal toxicity. The recommended taletrectinib dose is 600 mg orally once daily on an empty stomach until disease progression or unacceptable toxicity. Taletrectinib pricing was not available, but fourteen 160 mg capsules of rival repotrectinib — the initial 2-week supply with daily dosages doubling afterwards — is $7,666.97, according to
Bloomberg
an hour ago
- Bloomberg
RFK Jr. Picks Eight New Members of CDC Vaccine Panel
Health and Human Services Secretary Robert F. Kennedy Jr. announced on X the names of eight new members of an expert panel that advises the federal government on vaccine policy. Kennedy removed all 17 former members of the panel on Monday.
